he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
Ivacaftor Tablets had estimated annual sales of USD 109 million in the US.
The drug will be manufactured at the group’s topical facility at Ahmedabad
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Dr. Bernstein will tap into her decades of leadership and strategy experience as she transitions into this new role at APhA
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date
Subscribe To Our Newsletter & Stay Updated
